BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Navin Fluorine International Ltd.’s Q4 FY21 Ebitda grew 23% YoY on low base and steady performance in contract research and manufacturing service and specialty chemicals.
It expects specialty chemicals revenue growth in mid-teens for FY22.
CRAMS will continue to grow albeit at a lower magnitude; it is sitting on projects for 25 molecules in phase one and two.
Gross profit margins have been range bound despite significant improvement in contribution from high value business, which is key to watch.
High performance product and multi-purpose plants could be delayed by one-quarter on second wave of Covid-19.
Company remains excited on new opportunities and plans for a new innovation centre outside India.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.